AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06540937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide Pill
Description: This is a single-arm, single-center, phase II clinical study. Primarily evaluated in advanced MEN-1 neuroendocrine tumors. The initial efficacy of leflunomide tablets in second-line treatment provided evidence for phase III clinical trials.
Study NCT02716415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calmoseptine Ointment
Description: A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment
Study NCT02716415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Destin Maximum Strength 40% Zinc
Description: A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment
Study NCT02151565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTEMS
Study NCT02378688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03264131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHEP
Description: Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles.
Study NCT01762800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol 50/250mcg
Description: Active, 50/250mcg, Twice daily (morning and evening)
Study NCT02151565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Study NCT02041325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
Study NCT02041325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
Study NCT02875379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurements
Description: Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
Study NCT03969160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Description: Imaginal exposure to mental imagery of phobic and neutral stimuli
Study NCT04768283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional balance and resistance training - 1
Description: Additional exercise program with balance and resistance training three times per week.~The balance training included exercises to improve static as well as dynamic balance ability, for 15-20 minutes.~The resistance training included exercises with weights (0,5, 1 or 2 kg), elastic resistance rubbers, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets.
Study NCT04768283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional balance and resistance training - 2
Description: Additional exercise program with balance and resistance training three times per week.~The balance training included exercises with static and dynamic balance training device Biodex Balance System TM SD, for 15-20 minutes. Exercises are performed with the following programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training.~The resistance training included exercises with HUR strength training machines, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets. Strength training was performed with the following exercises: Leg press, leg extension, leg abduction, leg adduction.
Study NCT03592680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
Study NCT03592680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
Study NCT01826656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tooth extraction
Description: Patients from both groups will follow the extraction of an hopeless tooth
Study NCT01826656 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: tooth extraction
Description: Patients from both groups will follow the extraction of an hopeless tooth
Study NCT01826656 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CBCT scan
Description: A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
Study NCT01826656 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CBCT scan
Description: A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
Study NCT01826656 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: DXA scan
Description: DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
Study NCT03182972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation
Description: Pre-post intervention
Study NCT01826656 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DXA scan
Description: DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
Study NCT01826656 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Panoramic radiograph
Description: As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
Study NCT01826656 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Panoramic radiograph
Description: As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
Study NCT02607618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclaprim
Description: Experimental treatment
Study NCT02607618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Active comparator
Study NCT00644150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Ai Shi Zi training
Description: This training uses a curriculum developed specifically for Project Ai Shi Zi and includes training in stigma; risk-reduction counseling; and quality HIV/STI diagnosis, treatment, and management. Physician training will consist of multiple components: an orientation workshop on fundamental knowledge and skills of HIV/STI treatment and prevention, a 3-month practice period, a 3-month post-practice seminar on preventive counseling, another 3-month practice period, and a 6-month post-practice seminar on clinical HIV and STI management. The practice periods will promote learning-by-doing to further enhance physicians' abilities to deliver high quality, integrated HIV/STI prevention and treatment. Post-practice seminars will allow participants to share experiences gained during the previous 3-month practice period.
Study NCT00644150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard care
Description: If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
Study NCT00644150 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
Study NCT00644150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient risk-reduction counseling
Description: On the initial visit, participants will receive HIV/STI risk-behavior counseling from the physician trained in Ai Shi Zi. The process is based on motivational interviewing techniques and will include discussing topics such as partner notification, HIV/STI prevention, and expected difficulties in changing behaviors. This risk-reduction model encourages the HIV/STI-infected or -uninfected person to develop a risk-reduction plan. The objective is to decrease the chance of infection for that individual and for others, too. Patients will develop a list of risk-reduction strategies to follow.
Study NCT00655538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 36 weeks
Study NCT00655538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: 600mg po daily for 36 weeks
Study NCT04367831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Prophylactic Dose
Description: Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~1. BMI \< 40 kg/m2: Enoxaparin 40 mg SC daily~2. BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~3. BMI > 50 kg/m2: Enoxaparin 60 mg SC q12h
Study NCT04367831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Infusion
Description: Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
Study NCT04367831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin SC
Description: Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
Study NCT04367831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin/Lovenox Intermediate Dose
Description: If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
Study NCT03351647 — intervention group
Intervention type: BIOLOGICAL
Intervention: Evaluation of biological predictive factors of clinical response to ustekinumab
Description: The clinical response is defined as a decrease in the Crohn's Disease Activity Index (CDAI) score ≥ 100 points or a decrease in the HBI score ≥ 3 points.
Study NCT02695251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low AGE meal
Description: Patients will receive a low AGE (eggs) meal
Study NCT02695251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High AGE meal
Description: Patients will receive a high (mixed nuggets) AGE (eggs) meal
Study NCT01762800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol placebo
Description: Placebo, Twice daily (morning and evening)
Study NCT00820742 — intervention group
Intervention type: DRUG
Intervention: Macugen
Description: Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
Study NCT01398566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SuperBetter play
Description: average 10 min of game play per day for 6 week period
Study NCT00838201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
Study NCT04348513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3 solution for injection
Description: For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.
Study NCT04348513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as with T3 solution for injection.
Study NCT00915863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Billroth-II-type reconstruction
Description: surgical procedure
Study NCT00915863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated Roux-en-Y type reconstruction
Description: surgical procedure
Study NCT00410761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib)
Description: once daily oral tablet
Study NCT01762800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide 18mcg
Description: Active, 18mcg, Once daily(morning)
Study NCT01762800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide placebo
Description: Placebo, Once daily(morning)
Study NCT01762800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg
Description: Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
Study NCT01054482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy
Description: Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op \& Post-Op (total 4 cycles)
Study NCT01054482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative concurrent chemoradiation therapy
Description: Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op \& Post-Op: 2 cycles (total 4 cycles).~Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
Study NCT03004911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProFibro (Mobile application)
Description: ProFibro, a mobile Android application in Brazilian Portuguese to promote self-care in patients with fibromyalgia
Study NCT03004911 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paper booklet
Description: A 64-page booklet with content similar to the mobile application
Study NCT03128242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration of oxytocin (24IU)
Study NCT03128242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intranasal administration of placebo (24IU)
Study NCT02912715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel releasing angioplasty balloon
Description: Paclitaxel releasing angioplasty balloon catheter is advanced through an introducer sheath and tracked over the wire until reaching the target lesion. The balloon can be precisely positioned by means of the radiopaque markers crimped on the inner shaft of the catheter. The catheter is dilated up to its intended diameter by inflating the balloon with a solution containing contrast media, causing a compression of the arterial plaque against the inner lining of the arterial wall and improving blood flow. After balloon inflation, the drug-carrier adheres to the arterial wall and facilitates the drug release to surrounding tissue. As there is no need for sustained release of Paclitaxel after the inflation, the drug carrier dissolves rapidly.
Study NCT04449627 — intervention group
Intervention type: OTHER
Intervention: Feeling Good Digital App
Description: Audio based tracks using Jacobson relaxation and mindfullness based cognitive therapy (MBCT) techniques including positive visualisation.
Study NCT04355403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalo Gyn gel in prefilled applicators
Description: One vaginal application of Hyalo Gyn gel every 3 days to a total of 12 consecutive weeks.
Study NCT02485132 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
Study NCT02103491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salt administration
Description: Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
Study NCT02103491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Study NCT01061359 — intervention group
Intervention type: DRUG
Intervention: Epirubicin: Observational Study
Description: Observational: Chemotherapy
Study NCT05425329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: I3.1
Description: Capsule containing bacterial strains Lactobacillus plantarum (CECT7484 and CECT7485) and Pediococcus acidilactici (CECT7483) at a ratio of 1:1:1.
Study NCT05425329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Capsule containing maltodextrin.
Study NCT04450940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACV survey
Study NCT03653793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Health Product: LivRelief Varicose Veins Cream
Description: This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
Study NCT03827486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (exercise)
Description: Exercise program according to the standard of care
Study NCT04450940 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Placebo survey
Study NCT03038126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CCHT
Description: Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
Study NCT03038126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standard clinical care
Study NCT03847935 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: A1 pulley release of finger
Study NCT03847935 — intervention group
Intervention type: PROCEDURE
Intervention: corticosteroid injections
Description: corticosteroid injection to A1 pulley
Study NCT03847935 — intervention group
Intervention type: OTHER
Intervention: Hand Therapy
Description: orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education,
Study NCT03847935 — intervention group
Intervention type: OTHER
Intervention: Modality Hand Therapy
Description: orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education, plus modalities such as ultrasound, iontophoresis
Study NCT04424667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: donor milk
Description: pasteurized donor milk
Study NCT04424667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: donor milk
Description: pasteurized donor milk
Study NCT06271044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: With radioiodine treatment
Description: Postoperative radioiodine not given
Study NCT06271044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: With postoperative radioiodine treatment
Description: Postoperative radioiodine given
Study NCT01597635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 GSK2586881
Description: Low dose GSK2586881 administered intravenously
Study NCT01597635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 GSK2586881
Description: Medium dose GSK2586881 administered intravenously
Study NCT01597635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3 GSK2586881
Description: Medium-High dose GSK2586881 administered intravenously